(4-Hydroxy-tetrahydro-pyran-4-yl)-acetic acid | 920297-23-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (4-Hydroxy-tetrahydro-pyran-4-yl)-acetic acid
• 英文别名: 2H-Pyran-4-acetic acid, tetrahydro-4-hydroxy-；2-(4-hydroxyoxan-4-yl)acetic acid
• CAS: 920297-23-0
• 化学式: C₇H₁₂O₄
• 分子量: 160.17
• InChiKey: MYDOETMBFGJORC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  、 trans-4-[2-(4-benzo[1,3]dioxol-4-yl-piperidin-1-yl)-ethyl]-cyclohexylamine hydrochloride 、 (4-Hydroxy-tetrahydro-pyran-4-yl)-acetic acid 生成 trans-N-{4-[2-(4-benzo[1,3]dioxol-4-yl-piperidin-1-yl)-ethyl]-cyclohexyl}-2-(4-hydroxy-tetrahydro-pyran-4-yl)-acetamide
  参考文献：
  名称：

  NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS

  摘要：

  本发明涉及式(I)的新型5-HT2A和D3受体的双重调节剂，其中n、Y、R1、R2、R3和R4如本文所述，以及其药学上可接受的盐和酯。此外，本发明涉及制造式(I)的化合物、含有它们的制药组合物以及它们作为药物的使用。

  公开号：

  US20120225868A1
• 作为产物：
  描述：

  ethyl 2-(4-hydroxytetrahydro-2H-pyran-4-yl)acetate 在 水 、 lithium hydroxide 、 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 (4-Hydroxy-tetrahydro-pyran-4-yl)-acetic acid
  参考文献：
  名称：

  ORGANIC COMPOUNDS

  摘要：

  该发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=紊乱）；该类化合物用于制备用于治疗依赖肾素活性疾病的药物配方；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的药物配方，和/或包括给予3,5-取代哌啶化合物的治疗方法，一种用于制造3,5-取代哌啶化合物的方法，以及其合成的新中间体和部分步骤。优选的化合物（也可以存在为盐）具有式I的结构，其中R1、R2、T、R3和R4如规范中定义。

  公开号：

  US20090233920A1

文献信息

• D3 AND 5-HT2A RECEPTOR MODULATORS
  申请人：Gobbi Luca

  公开号：US20100075983A1

  公开（公告）日：2010-03-25

  The present invention provides compounds of the general formula (I) wherein X, n and R 1 are as described herein, as well as pharmaceutically acceptable salts and esters thereof, methods for their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are dual modulators of the serotonin 5-HT 2a and dopamine D 3 receptors, useful in the treatment and/or the prevention of cognitive disorders, drug addiction, depression, anxiety, drug dependence, dementias, memory impairment, psychotic disorders comprising schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and psychoses comprising paranoia and delusions.

  本发明提供了一般式(I)的化合物，其中X、n和R1如本文所述，以及其药学上可接受的盐和酯，其制备方法，含有它们的药物组合物以及它们作为药物的用途。本发明的活性化合物是血清素5-HT2a和多巴胺D3受体的双调节剂，在认知障碍、药物成瘾、抑郁症、焦虑症、药物依赖、痴呆症、记忆障碍、包括精神分裂症、情感性精神障碍、双相情感障碍、躁狂症、精神抑郁症以及偏执狂和妄想的精神病等的治疗和/或预防中有用。
• [EN] NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS BENZODIOXOLE PIPÉRIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012117001A1

  公开（公告）日：2012-09-07

  The present invention is concerned with novel dual modulators of the 5-HT2A and D3 receptors of formula (I) wherein n, Y, R1, R2, R3, and R4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.

  本发明涉及公式（I）中5-HT2A和D3受体的新型双调节剂，其中n、Y、R1、R2、R3和R4如本文所述，以及其药学上可接受的盐和酯。此外，本发明涉及制备公式（I）化合物、包含它们的药物组合物以及它们作为药物的用途。
• NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS
  申请人：Rodriguez Sarmiento Rosa Maria

  公开号：US20120225868A1

  公开（公告）日：2012-09-06

  The present invention is concerned with novel dual modulators of the 5-HT 2A and D 3 receptors of formula (I) wherein n, Y, R 1 , R 2 , R 3 , and R 4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions containing them and their use as pharmaceuticals.

  本发明涉及一种新颖的5-HT2A和D3受体的双重调节剂，其化学式为（I），其中n、Y、R1、R2、R3和R4如本文所述，以及其药学上可接受的盐和酯。此外，本发明涉及化合物（I）的制备、含有它们的药物组合物以及它们作为药物的用途。
• Substituted aryl cycloalkanol derivatives and methods of their use
  申请人：Trybulski John Eugene

  公开号：US20050143579A1

  公开（公告）日：2005-06-30

  The present invention is directed to substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及取代芳基环烷酰衍生物，含有这些衍生物的组合物，以及它们的使用方法，用于预防和治疗由单胺再摄取改善的病况，包括但不限于血管运动症状（VMS），性功能障碍，胃肠和泌尿系统疾病，慢性疲劳综合症，纤维肌痛综合症，神经系统疾病和其组合，特别是从包括重度抑郁症、血管运动症状、压力和切望性尿失禁、纤维肌痛、疼痛、糖尿病神经病变和其组合的一组疾病中选择的那些病状。
• Fused Quinoline Derivative and Use Thereof
  申请人：Kajino Masahiro

  公开号：US20080039452A1

  公开（公告）日：2008-02-14

  The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein R 1 is a hydrogen atom and the like; R 2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R 3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R 4 and R 5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R 6 is (cyclic group optionally having substituent(s))-carbonyl, and the like; R 7 , R 8 , R 9 and R 10 are the same or different and each is a hydrogen atom, halogen and the like; or R 7 and R 8 , R 8 and R 9 , and R 9 and R 10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; --- represents unsubstituted (i.e., absence) or a single bond; and represents a single bond or a double bond, or a salt thereof, and the like.

  本发明旨在提供一种具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，涉及一种由式（I）表示的化合物，其中R1为氢原子等；R2为氢原子、烃基可选地具有取代基等；R3为未取代（即不存在）、氢原子等；R4和R5相同或不同，每个都是氢原子、烃基可选地具有取代基等；R6为（环状基团可选地具有取代基）-羰基等；R7、R8、R9和R10相同或不同，每个都是氢原子、卤素等；或R7和R8、R8和R9以及R9和R10可以与相邻的碳原子一起形成环；n为1到5的整数；---表示未取代（即不存在）或单键；表示单键或双键，或其盐等。